Cathelicidin (LL-37) vs Dermaseptin — mechanism, half-life, dosing, and research status compared. Which is right for your protocol?
LL-37 is the sole human cathelicidin antimicrobial peptide, derived by proteolytic cleavage of the 18 kDa precursor hCAP18 (encoded by the CAMP gene). It is produced by neutrophils, epithelial cells of the skin, gut, and airways, and mast cells....
Calculate Cathelicidin (LL-37) dose →Dermaseptins are a family of 28-34 amino acid antimicrobial peptides first isolated from the skin of South American Phyllomedusa frogs. They are among the most potent broad-spectrum AMPs known, with activity against bacteria, fungi, protozoa, and viruses....
Calculate Dermaseptin dose →| Parameter | Cathelicidin (LL-37) | Dermaseptin |
|---|---|---|
| Category | Antimicrobial Peptide | Antimicrobial Peptide |
| Research | Clinical Research | Preclinical |
| Half-Life | < 10 min (plasma) | Minutes (proteolytic) |
| Typical Dose | Research: 1-100 ug/mL (topical) | N/A (research) |
| Frequency | Varies by application | N/A |
| Route | Endogenous; topical/inhalation (research) | Topical / Parenteral (research) |
| FDA Status | No approval (clinical trials ongoing) | Not approved |
Use ASCEND's free reconstitution calculator to get exact syringe draw amounts for your vial.
For research use only. Not medical advice. ASCEND does not conduct or endorse any specific research protocol. Always consult relevant scientific literature and regulatory guidelines.